TTrialPathMatch Me to Trials
← Back to trials
RecruitingBreast CancerHER2-positive Breast Cancer

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Eligible age

18+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel

Sponsor: Dana-Farber Cancer Institute

You may qualify if…

  • ✓ Patients must have HER2-positive Stage I histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mic) breast cancer according to the AJCC 8th edition anatomic staging table.
  • ✓ If the patient has had a negative sentinel node biopsy, then no further axillary dissection is required, and the patient is determined to be node-negative. If an axillary dissection without sentinel lymph node biopsy is performed to determine nodal status, at least six axillary lymph nodes must be removed and analyzed, and determined to be negative, for the patient to be considered node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H\&E or immunohistochemistry (IHC) will be considered node-negative.
  • ✓ Any axillary lymph node with tumor clusters between 0.02 and 0.2 cm is considered a micrometastasis. Patients with a micrometastasis are eligible. An axillary dissection is not required to be performed in patients with a micrometastasis found by sentinel node evaluation. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the principal investigator will make the final determination as to eligibility. The investigator must document approval in the patient medical record.
  • ✓ Patients who have an area of a T1aN0, ER+ (defined as \>10%), HER2-negative cancer in addition to their primary HER2-positive tumor are eligible.
  • ✓ HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing. NOTE: HER-2 status must be confirmed to be positive by central review by NeoGenomics prior to patient starting protocol therapy. Patients previously having had HER2 immunohistochemical testing by NeoGenomics do not need to undergo retesting for central confirmation of HER2 status.
  • ✓ NOTE: DCIS components will not be counted in the determination of HER2 status
  • ✓ ER/PR determination is required. ER and PR assays should be performed by immunohistochemical methods according to the local institution standard protocol.
  • ✓ Bilateral breast cancers that individually meet eligibility criteria are allowed.

You may not qualify if…

  • ✕ Any of the following due to teratogenic potential of the study drugs:
  • ✕ Pregnant women
  • ✕ Nursing women
  • ✕ Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDs, surgical sterilization, abstinence, etc.).
  • ✕ Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc.).
  • ✕ Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
  • ✕ Patients with a history of previous invasive breast cancer.
  • ✕ History of prior chemotherapy in the past 5 years.

Where it's recruiting

California

San Francisco

Connecticut

Derby · Fairfield · Glastonbury · Greenwich …

Florida

Miami · Plantation

Illinois

Chicago

Indiana

Carmel · Indianapolis

Maine

Brewer · Scarborough

Massachusetts

Boston · Brighton · Burlington · Danvers …

New Hampshire

Concord · Londonderry · Manchester · Portsmouth

New York

Brooklyn · Mineola · New York

North Carolina

Durham · Raleigh

Ohio

Columbus

Pennsylvania

Philadelphia · Pittsburgh

Source: ClinicalTrials.gov · NCT04893109 · last updated 2026-08-19

ATEMPT 2.0: Adjuvant T-DM1 vs TH · TrialPath